Aminolevulinic acid - Biofrontera

Drug Profile

Aminolevulinic acid - Biofrontera

Alternative Names: 5-Aminolevulinic acid - Biofrontera; Ameluz; Aminolevulinic acid hydrochloride - Biofrontera; BF-200 ALA

Latest Information Update: 05 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ASAT AG
  • Developer Biofrontera AG; Louis Widmer
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Actinic keratosis; Basal cell cancer
  • No development reported Condylomata acuminata

Most Recent Events

  • 29 Jan 2018 Biofrontera receives positive opinion from the CHMP for label extension of aminolevulinic acid in combination with daylight photodynamic therapy
  • 23 Jan 2018 Interim efficacy data from a phase III trial for Actinic keratosis released by Biofrontera
  • 19 Dec 2017 Biofrontera plans a phase III trial in superficial Basal cell carcinoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top